ArticleBlood advances2021
Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium.
Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06756061 (A Nation-wide, Multi-center, Prospective, Randomized, Parallel-group, Open-label, Investigator Initiated Pilot Study to Evaluate Efficacy and Safety of Systemic Corticosteroid Plus Ruxolitinib as First-line Therapy in Patients With New-onset Moderate to Severe Chronic Graft-versus-host Disease), which is not on this map. Cited by 81 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Nation-wide, Multi-center, Prospective, Randomized, Parallel-group, Open-label, Investigator Initiated Pilot Study to Evaluate Efficacy and Safety of Systemic Corticosteroid Plus Ruxolitinib as First-line Therapy in Patients With New-onset Moderate to Severe Chronic Graft-versus-host Disease
Who cites it
81 citing papers in PubMed, 1 synthesis or guideline pooled it, 130 citations in OpenAlex.
- Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Pooled it
- Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial.The Lancet. Haematology · 2026Trial
- Novel highly selective ROCK2 inhibitor (TDI01) for the treatment of chronic graft-versus-host disease: a multicenter, open-label phase Ib/II study.Signal transduction and targeted therapy · 2026Trial
- Phase 1/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease.Blood advances · 2026Trial
- Exposure-Response Relationships for Axatilimab in Patients with Chronic Graft-Versus-Host Disease.Clinical pharmacology and therapeutics · 2025Trial
- Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3.Blood advances · 2025Trial
- Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin.The New England journal of medicine · 2025Trial
- Belumosudil for Chronic Graft-Versus-Host Disease: Analysis of Long-Term Results from the KD025-208 and ROCKstar Studies.Transplantation and cellular therapy · 2025Trial
- A phase 2 multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic HCT.Blood advances · 2025Trial
- "They knew the same struggles": perceptions of a group coping skills intervention in patients with chronic graft-versus-host disease.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Trial
- Group Coping Intervention in Patients With Chronic Graft-Versus-Host Disease: A Pilot Randomized Clinical Trial.Journal of the National Comprehensive Cancer Network : JNCCN · 2024Trial
- Mesenchymal Stem Cells for Prophylaxis of Chronic Graft-vs-Host Disease After Haploidentical Hematopoietic Stem Cell Transplant: An Open-Label Randomized Clinical Trial.JAMA oncology · 2024Trial
- Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic GVHD: results from a multicenter retrospective analysis of a large German-Austrian cohort of the belumosudil MAP.Bone marrow transplantation · 2026Article
- Bronchiolitis Obliterans Syndrome After Allogeneic HSCT: Clinical Characteristics and Survival Outcomes in a Single Center Cohort.Journal of clinical medicine · 2026Article
- Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients.Bone marrow transplantation · 2026Observational
- CAR19 Tregs treat murine chronic graft-versus-host disease through immune suppression without measurable B cell cytolysis.JCI insight · 2026Article
- Real-world outcomes in refractory chronic graft-Haematologica · 2026Article
- Belumosudil for Long-Standing Refractory Chronic Graft-Versus-Host Disease: A Two-Patient Case Report.Clinical case reports · 2026Article
- Chronic graft-versus-host disease.Nature reviews. Disease primers · 2026Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 1 country.
Funding
Abstract
Chronic graft-versus-host disease (cGVHD) is the leading cause of late morbidity and mortality after allogeneic hematopoietic cell transplantation. To better understand patients at highest risk for nonrelapse mortality (NRM), we analyzed patient-, transplant-, and cGVHD-related variables, risk factors, and causes of nonrelapse deaths in an updated cohort of 937 patients enrolled on 2 prospective, longitudinal observational studies through the Chronic GVHD Consortium. The median follow-up of survivors was 4 years (range, 0.1 months to 12.5 years). Relapse accounted for 25% of the 333 deaths. The cumulative incidence of NRM was 22% at 5 years, and it increased over time at a projected 40% (95% confidence interval, 30%-50%) at 12 years. Centers reported that cGVHD (37.8%) was the most common cause of NRM and was associated with organ failure, infection, or additional causes not otherwise specified. The next most frequent causes without mention of cGVHD were infection (17%) and respiratory failure (10%). In multivariable analysis, an increased risk for NRM was significantly associated with the use of reduced intensity conditioning, higher total bilirubin, National Institutes of Health (NIH) skin score of 2 to 3, NIH lung score of 1 to 3, worse modified Human Activity Profile adjusted activity score, and decreased distance on walk test. To summarize, cGVHD NRM does not plateau but increases over time and is most commonly attributed to GVHD or infection, presumably associated with immunocompromised status. Severe skin and lung cGVHD remain challenging manifestations associated with increased NRM, for which novel therapeutic options that do not predispose patients to infections are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.